Assessing current AI trends in drug development: Adoption and transformation (part 1)
Pharmaceutical R&D is undergoing significant changes. The need to accelerate drug development and enhance decision-making has placed artificial intelligence (AI) at the core of industry transformation. According to Norstella’s State of the Industry AI survey, 2024, 81% of organizations already use AI in at least one development program. This reveals that AI is rapidly becoming […]
Conference catch-up: The rise of digital therapeutics (part 2)
Health technologies are revolutionizing the ways in which life sciences organizations develop and deliver life-saving treatments to patients. In particular, digital therapeutics have become a prominent area of focus due to their potential to improve outcomes while reducing patient burden. Norstella continues to be proponent for these innovative technologies, partnering with organizations to launch their […]
The current & future impact of AI on pharmaceutical R&D
Artificial intelligence (AI) continues to disrupt existing paradigms in drug development, with early adopters experiencing both the benefits and challenges of this innovative technology. With that in mind, Norstella surveyed 125 senior decision-makers in the life sciences industry on their perceptions and expectations of AI to understand current AI adoption trends in addition to the […]
Norstella rolls out NorstellaLinQ data platform
Norstella LinQ establishes a throughline between the company’s various subsidiaries, utilizing capabilities from Citeline, Evaluate, MMIT, Panalgo and The Dedham Group. Norstella debuted its NorstellaLinQ data platform on Tuesday, an offering from the pharmaceutical intelligence solutions provider that aggregates and cleans real-world data from various sources to provide high quality, comprehensive patient information. Utilizing Norstella’s […]
The practice-changing drugs that will land in 2025
2025 promises to represent another rich year of progress. A wealth of new therapies are set to successfully graduate from the pipeline. Within this cohort are a mixture of therapeutic areas, drug classes, first-time approvals, label expansions, and most importantly treatments that will meaningfully change how diseases are treated. This article provides a snapshot of […]
Conference catch-up: The rise of digital therapeutics (part 1)
Healthcare technologies are revolutionizing the ways in which life sciences organizations develop and deliver life-saving treatments to patients. In particular, digital therapeutics have become a prominent area of focus due to their potential to improve outcomes while reducing patient burden. Norstella continues to be proponent for these innovative technologies, partnering with organizations to launch their […]
Pharma’s future: More with less
2023 saw the biopharmaceutical industry spend a record $300bn on R&D activities, reinvesting approximately 30% of prescription revenues to secure the next generation of therapies. Yet, recent weeks have seen falling valuations and stark anecdotes from contract research organizations as their main client base – large pharma companies – have tightened the belt on early […]